Although all eyes have been on the searing path that benchmark equity indices have blazed in 2021, initial public offerings (IPOs) have had their own impressive bull market. In fact, Reuters reported in mid-June that U.S. IPOs hit an annual record in less than six months. So if 2020 was the year of the novel
admin
Palantir Technologies (NYSE:PLTR) hasn’t fully recovered since pulling back with the overall market in late September. But PLTR stock has still managed to slowly move higher in recent weeks. Source: Ascannio / Shutterstock.com To some extent, this uptrend makes sense. After all, the “story” behind this stock remains intact. The company has continued to post strong
The renewable energy industry is booming. While it only supplies less than a quarter of the power generated today, this will change drastically by 2040. Its share is expected to grow in excess of 40% by 2040, as new technologies are developed for wind and solar energy production. Therefore, in line with the fast-changing energy
In this article F CZR SHOO Ford CEO Jim Farley poses with the Ford F-150 Lightning pickup truck in Dearborn, Michigan, May 19, 2021. Rebecca Cook | Reuters It seems each passing trading session brings a torrent of quarterly earnings and sharp swings for the stocks of the companies reporting results. Positive prints can have
In this article QCOM QRVO Medical syringe is seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland. Jakub Porzycki | NurPhoto | Getty Images Check out the companies making headlines in midday trading. Moderna — Moderna shares tumbled 19% after a weaker-than-expected quarterly report. The drug
I first came in contact with Palantir (NYSE:PLTR) stock earlier this year and immediately knew it was something special. The underlying bullish thesis was clear, so I traded it successfully in the past few months. The easiest opportunities came when it fell in sympathy to other small-cap stocks. Source: Ascannio / Shutterstock.com The problem with
Virgin Galactic (NYSE:SPCE) has been on a bad downward spiral. From a recent peak of $55.91 on June 25, SPCE stock is now near a low point of $19.55. However, despite this, don’t act on the urge just yet to bargain hunt in this stock. Source: rafapress / Shutterstock.com I forewarned investors that this could
After an incredible run-up in the days after its initial public offering, volatility in Robinhood (NASDAQ:HOOD) is mostly absent. That did not stop the bearish selling on HOOD stock from accelerating after the company posted quarterly results on Oct. 26. Source: OpturaDesign / Shutterstock.com Robinhood fell after posting third-quarter results. What did investors not like?
Jeff Bezos, left, and Elon Musk Getty Images; Reuters The U.S. Federal Court of Claims ruled against Jeff Bezos’ Blue Origin in the company’s lawsuit versus NASA over a lucrative astronaut lunar lander contract awarded to Elon Musk’s SpaceX earlier this year. Federal judge Richard Hertling sided with the defense in his ruling, completing a
In this article GOOS-CA DKNG PFE LYV WEED-CA PTON Check out the companies making headlines before the bell: Pfizer (PFE) – The drug maker’s shares surged 9.4% in premarket trading after a study showed that its experimental Covid-19 antiviral pill reduced the risk of hospitalization and death by nearly 90%. Pfizer said it will ask
We highlight four ETFs that are benefitting from increasing adoption of automation & AI
The cost of healthcare can be overwhelming. Even with insurance, individuals and families often find themselves spending a significant amount of money on medical costs. The average family of four with employer-provided insurance and an income of $100,000 will likely pay $12,500 in healthcare expenses. This equates to roughly 13% of the family’s income. Flexible
When I last wrote about QuantumScape (NYSE:QS) in late September, I argued that if you could afford to lose it all, QS stock at $23.50 was in the buy zone. As I write this, it’s up 33% in the past month, trading above $30 for the first time since late June. Source: Michael Vi /
Ocugen (NASDAQ:OCGN) is a stock that I continue to be wrong about. Over the past month, OCGN stock has gained more than 80%, greatly testing my patience. The stock has fallen from the $17 mark it reached this morning, but is still higher than I expected last month. Source: shutterstock.com/PhotobyTawat In my last article about
It has been an excellent third-quarter earnings season so far. Of the S&P 500 stocks that have reported earnings, a majority have beaten analyst estimates. According to Factset Insight, 56% of the index companies have reported earnings so far in Q3 2021. Of those, 82% beat the consensus earnings per share (EPS). That’s higher than
Prasit photo | Moment | Getty Images Sustainable investing has come into focus as investors direct their cash toward stocks based on so-called ESG factors, but shareholders will need to get involved to create meaningful change at companies. U.S. sustainable funds saw $15.7 billion in net inflows during the third quarter of 2021, according to
Workers at Stellantis’ Detroit Assembly plant which produces the new 2021 Grand Cherokee L, a new three-row SUV. Michael Wayland | CNBC Broad-based strength in hiring in October signals the economy is shaking off the Covid-related slump of the third quarter and could grow faster than expected in the fourth quarter. Employment increased by 531,000
As frequent InvestorPlace readers know, I’ve spent a lot of time covering the lidar space as part of my Behind the Wall series. As such, Microvision (NASDAQ:MVIS) — a key player in the world of lidar — has had a large role in my conversations about, and analyses of, lidar stocks. Source: temp-64GTX/Shutterstock.com So, when
If you’ve read my prior articles on Ocugen (NASDAQ:OCGN), you know full well my heavily bearish view about OCGN stock. What’s the story here? The company is trying to bring Covaxin, a Covid-19 vaccine candidate developed by India’s Bharat Biotech, to the U.S. and Canada. Source: shutterstock.com/PhotobyTawat So far, it’s made little progress obtaining Emergency
Shares in Houston-based Tellurian (NYSEAMERICAN:TELL) have been riding the natural gas wave. Since mid-August, TELL stock has posted a 65% gain. It’s more than tripled its share price since the start of the year. However, despite rallying for the better part of three months, it remains well off its high close of $5.32 in June.